Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMRAW vs FREQ, BNTC, IMNN: Days Payable Comparison
For the Biotechnology subindustry, Comera Life Sciences Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Comera Life Sciences Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Comera Life Sciences Holdings's Days Payable falls into.
Comera Life Sciences Holdings Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Comera Life Sciences Holdings (CMRAW) has a Days Payable of 3,580.48 as of Sep. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Comera Life Sciences Holdings and its competitors. This is 513% above median its historical median of 583.77. Over the past decade, Comera Life Sciences Holdings' Days Payable has ranged from 343.94 to 2,193.58.
Is Comera Life Sciences Holdings' Days Payable too high?
Comera Life Sciences Holdings' current Days Payable of 3,580.48 is 513% above median its 10-year median of 583.77. Over the past 10 years, this metric has ranged from a low of 343.94 to a high of 2,193.58. The Biotechnology industry median Days Payable is 111.42. Comera Life Sciences Holdings' value of 3,580.48 is 3113.5% above this industry median. Overall, Comera Life Sciences Holdings has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Comera Life Sciences Holdings' Days Payable compare to FREQ and BNTC?
Comera Life Sciences Holdings' Days Payable of 3,580.48 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 111.42. Comera Life Sciences Holdings' value of 3,580.48 is 3113.5% above this benchmark. Historically, Comera Life Sciences Holdings' own Days Payable has ranged from 343.94 to 2,193.58 over the past decade. While the company's 10-year median is 583.77 vs. the industry median of 111.42, Comera Life Sciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.42, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Comera Life Sciences Holdings's current Days Payable of 3,580.48 is 3113.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Comera Life Sciences Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 111.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Comera Life Sciences Holdings's current Days Payable is 3,580.48, which is 513% above median its own 10-year median of 583.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Comera Life Sciences Holdings stock overvalued right now?
Comera Life Sciences Holdings (CMRAW) has a current Days Payable of 3,580.48. The current Days Payable is 3,580.48, which is 513% above median its 10-year median of 583.77 and 3113.5% above the Biotechnology industry median of 111.42. Comera Life Sciences Holdings' overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Comera Life Sciences Holdings (CMRAW), the current Days Payable is 3,580.48 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
16GF Score
Get the complete analysis for CMRAW
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMRAW has been successfully added to your 
